Logo

Kyowa Kirin's Istradefylline (KW-6002) Receives EMA's MAA as an Adjunctive Treatment to Levodopa-Based Regimens in Adult with Parkinson's disease Experiencing “Off” Time

Share this
Kyowa Kirin's Istradefylline (KW-6002) Receives EMA's MAA as an Adjunctive Treatment to Levodopa-Based Regimens in Adult with Parkinson's disease Experiencing “Off” Time

Kyowa Kirin's Istradefylline (KW-6002) Receives EMA's MAA as an Adjunctive Treatment to Levodopa-Based Regimens in Adult with Parkinson's disease Experiencing “Off” Time

Shots:

  • The approval is based on trials assessing KW-6002 vs PBO across EU- the US and Japan in patients with PD taking a stable dose of levodopa-based regimens with/out other PD medications
  • The candidate will serve as an adjunctive treatment to the PD patients which is validated by the EMA and is now under review
  • Istradefylline is a selective adenosine A2A receptor antagonist administered orally and is approved in Japan & the US in Mar 2013- & Aug 2019- to improve “wearing-off” phenomenon in patients with PD on levodopa-containing preparations and as an adjunctive treatment to levodopa/carbidopa in adults with PD experiencing “off” episodes respectively

Click here to read full press release/ article | Ref: Kyowa Kirin | Image: Twitter


Tuba

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions